Unnur Valdimarsdóttir

Unnur Valdimarsdóttir

Auto-generated profile, based on publicly available information

Unnur Valdimarsdóttir

Unit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Clinical Epidemiology
Verified
Journal Article
Open access
PDF file
KLKristina Laugesen
Kristina Laugesen
JLJohnny Ludvigsson
Johnny Ludvigsson
MSMorten Schmidt
Morten Schmidt
MGMika Gissler
Mika Gissler
UVUnnur Anna Valdimarsdottir
Unnur Anna Valdimarsdottir
Henrik Toft SørensenHenrik Toft Sørensen
Henrik Toft Sørensen
The Nordic countries are Denmark, Finland, Iceland, Norway, and Sweden and comprise a total population of approximately 27 million. The countries provide unique opportunities for joint health registry-based research in large populations with long and complete follow-up, facilitated by shared features, such as the tax-funded and public health care systems, the similar population-based registries, and the personal identity number as unique identifier of all citizens. In this review, we provide an introduction to the health care systems, key registries, and how to navigate the practical and ethical aspects of setting up such studies. For each country, we provide an overview of population statistics and health care expenditures, and describe the operational and administrative organization of the health care system. The Nordic registries provide population-based, routine, and prospective data on individuals lives and health with virtually complete follow-up and exact censoring information. We briefly describe the total population registries, birth registries, patient registries, cancer registries, prescription registries, and causes of death registries with a focus on period of coverage, selected key variables, and potential limitations. Lastly, we discuss some practical and legal perspectives. The potential of joint research is not fully exploited, mainly due to legal and practical difficulties in, for example, cross-border sharing of data. Future tasks include clear and transparent legal pathways and a framework by which practical aspects are facilitated.

5 April 2012 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
FFFang Fang
Fang Fang
KFKatja Fall
Katja Fall
MMMurray A. Mittleman
Murray A. Mittleman
PSPär Sparén
Pär Sparén
WYWeimin Ye
Weimin Ye
UVUnnur Valdimarsdóttir
Unnur Valdimarsdóttir
Receiving a diagnosis of cancer is a traumatic experience that may trigger immediate adverse health consequences beyond the effects of the disease or treatment.

19 June 2018 in JAMA
Verified
Journal Article
Open access
PDF file
HSHuanlu Song
Huanlu Song
FFFang Fang
Fang Fang
GTGunnar Tomasson
Gunnar Tomasson
FAFilip K. Arnberg
Filip K. Arnberg
DMDavid Mataix-Cols
David Mataix-Cols
UVUnnur A. Valdimarsdóttir
Unnur A. Valdimarsdóttir
Most humans are at some point during their lives exposed to trauma or significant life stressors, including loss of loved ones and exposure to various disasters or violence.1,2 While many individuals exposed to such adversities gradually recover,1,3 a significant proportion goes on to develop severe psychiatric reactions, including posttraumatic stress disorder (PTSD) or acute stress reaction (also known as acute stress disorder) after life-threatening events,4 or adjustment disorder triggered by an identifiable and stressful life change.5 Individuals with such stress-related disorders experience an array of physiologic alterations, including disruption of the hypothalamic-pituitary-adrenal axis6 and autonomic nervous system,6,7 which in turn may influence multiple bodily systems, eg, immune function,6,8 and thereby susceptibility to disease.

16 September 2004 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
UKUlrika Kreicbergs
Ulrika Kreicbergs
UVUnnur Valdimarsdóttir
Unnur Valdimarsdóttir
EOErik Onelöv
Erik Onelöv
JHJan-Inge Henter
Jan-Inge Henter
GSGunnar Steineck
Gunnar Steineck
One of the questions faced by the parents of a child who is terminally ill with a malignant disease is whether or not they should talk about death with their child.

18 April 2024 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
CNCaroline Nievergelt
Caroline Nievergelt
AMAdam X. Maihofer
Adam X. Maihofer
EAElizabeth G. Atkinson
Elizabeth G. Atkinson
CCChia-Yen Chen
Chia-Yen Chen
KCKarmel W. Choi
Karmel W. Choi
KKKarestan C. Koenen
Karestan C. Koenen

12 January 2011 in BMJ
Verified
Journal Article
Open access
PDF file
HKHelle Kieler
Helle Kieler
MAMiia Artama
Miia Artama
AEAnders Engeland
Anders Engeland
ÖEÖrjan Ericsson
Örjan Ericsson
KFKari Furu
Kari Furu
BHBengt Haglund
Bengt Haglund
Objective To assess whether maternal use of selective serotonin reuptake inhibitors (SSRIs) increases the risk of persistent pulmonary hypertension in the newborn, and whether such an effect might differ between specific SSRIs. Design Population based cohort study using data from the national health registers. Setting Denmark, Finland, Iceland, Norway, and Sweden, 1996-2007. Participants More than 1.6 million infants born after gestational week 33. Main outcome measures Risks of persistent pulmonary hypertension of the newborn associated with early and late exposure to SSRIs during pregnancy and adjusted for important maternal and pregnancy characteristics. Comparisons were made between infants exposed and not exposed to SSRIs. Results Around 30 000 women had used SSRIs during pregnancy and 11 014 had been dispensed an SSRI later than gestational week 20. Exposure to SSRIs in late pregnancy was associated with an increased risk of persistent pulmonary hypertension in the newborn: 33 of 11 014 exposed infants (absolute risk 3 per 1000 liveborn infants compared with the background incidence of 1.2 per 1000); adjusted odds ratio 2.1 (95% confidence interval 1.5 to 3.0). The increased risks of persistent pulmonary hypertension in the newborn for each of the specific SSRIs (sertraline, citalopram, paroxetine, and fluoxetine) were of similar magnitude. Filling a prescription with SSRIs before gestational week 8 yielded slightly increased risks: adjusted odds ratio 1.4 (95% confidence interval 1.0 to 2.0). Conclusions The risk of persistent pulmonary hypertension of the newborn is low, but use of SSRIs in late pregnancy increases that risk more than twofold. The increased risk seems to be a class effect.